Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as HP184
Nerispirdine · 3 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| Nerispirdine 50mg | EXPERIMENTAL | Nerispirdine 50mg once daily for 14 weeks |
| Nerispirdine 100mg | EXPERIMENTAL | Nerispirdine 100mg once daily for 14 weeks |
| Nerispirdine 200mg | EXPERIMENTAL | Nerispirdine 200mg once daily for 14 weeks |
| Placebo | PLACEBO_COMPARATOR | Placebo for Nerispirdine once daily for 14 weeks |
| Sequence 1 | EXPERIMENTAL | placebo,1 day treatment period 1 50 mg Nerispirdine, 1 day treatment period 2 400 mg Nerispirdine, 1 day treatment period 3 |
| Sequence 2 | EXPERIMENTAL | placebo,1 day treatment period 1 400 mg Nerispirdine, 1 day treatment period 2 50 mg Nerispirdine, 1 day treatment period 3 |
| Sequence 3 | EXPERIMENTAL | 50 mg Nerispirdine, 1 day treatment period 1 placebo, 1 day treatment period 2 400 mg Nerispirdine, 1 day treatment period 3 |
| Sequence 4 | EXPERIMENTAL | 50 mg Nerispirdine, 1 day treatment period 1 400 mg Nerispirdine, 1 day treatment period 2 placebo, 1 day treatment period 3 |
| Sequence 5 | EXPERIMENTAL | 400 mg Nerispirdine, 1 day treatment period 1 placebo, 1 day treatment period 2 50 mg Nerispirdine, 1 day treatment period 3 |
| Sequence 6 | EXPERIMENTAL | 400 mg Nerispirdine, 1 day treatment period 1 50 mg Nerispirdine, 1 day treatment period 2 placebo, 1 day treatment period 3 |
| Name | Type | Description |
|---|---|---|
| Nerispirdine | DRUG | tablet, oral administration |
| placebo | DRUG | tablet, oral administration |
| HP184 | DRUG | - |
Inclusion Criteria: * Clinically definite MS (according to McDonald criteria), Exclusion Criteria: * Multiple sclerosis exacerbation or clinical relapse within 6-month prior to the screening visit. * Subject who is not able to complete two trials of a timed 25 foot walk, with or without an assist...
Top 17 of 21 competitors
Nerispirdine is an investigational small molecule developed by Sanofi for multiple sclerosis. It is a potassium channel blocker that has been studied in Phase 2 clinical trials. It is not approved for any indication and remains in clinical development.
Nerispirdine was studied as a treatment for multiple sclerosis, including patients with optic nerve involvement such as neuritis. Both Phase 2 trials enrolled adults with MS. It is investigational and has not been approved for treating multiple sclerosis or any other condition.
Nerispirdine is a blocker of several potassium channels, specifically KCNQ1, KCND3, KCNH2, KCNA2, KCNA1, and KCNQ2. By blocking these channels, it is designed to modulate nerve signal conduction, which is the rationale for studying it in multiple sclerosis.
Nerispirdine is developed by Sanofi, which trades on the New York Stock Exchange under the ticker SNY. Sanofi sponsored both Phase 2 trials of the drug in multiple sclerosis.
Nerispirdine is in Phase 2 development. Two Phase 2 trials have been completed, and no trials are currently active. The drug is investigational and has not received FDA approval for any indication.
Nerispirdine has been evaluated in two completed Phase 2 trials. NCT00811902 tested efficacy, safety, and tolerability in 405 patients with multiple sclerosis across the United States, Canada, and several European countries. NCT00772525 studied single oral doses and visual function in 31 patients with multiple sclerosis and optic neuritis in the United States.